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Background: Cystic fibrosis (CF) specific patient-derived and reported symptom tools are critical steps toward evaluating the outcomes of new
therapies for CF.
Methods: We conducted 25 in-depth qualitative interviews using the Day Reconstruction Method and 9 cognitive interviews at two CF programs,
the University of Washington and Seattle Children's Hospital and Regional Medical Center. The interviews were audio-recorded and transcribed,
and then coded and analyzed for themes relating to pulmonary symptoms and related psychosocial impacts.
Results: Six pulmonary symptoms were identified as central to CF: cough, sputum production, wheeze, chest tightness, difficulty breathing/
shortness of breath, and fever. Emotional impacts included frustration, sadness/depression, irritability, worry, difficulty sleeping; while activity
impacts included time spent sitting or lying down, reduction of usual activities, and missing school or work. In all, 8 symptom items, 4 emotional
impacts items, and 4 activity impacts were selected for inclusion on a new daily diary. We also assessed triggers for seeking care.
Conclusions: Using a qualitative inductive methodology, we have obtained patient centered data regarding pulmonary symptoms and burdens and
have created a novel patient reported outcome measure for CF. Future studies will assess the validity of the instruments.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Qualitative study; Respiratory symptoms; Patient reported outcomes1. Introduction
Over the past thirty years in the United States, the median
age of survival with cystic fibrosis (CF) has more than doubled
from 14 years in 1969 to 36.9 years in 2006. With improved
survival, this disease has been transformed from a disease with
very high infant mortality to a disease that must now be
considered a chronic lung disease. Acute pulmonary exacerba-
tions are at the core of the care of the management of CF
patients. Surprisingly, there is no consensus definition of an
acute pulmonary exacerbation [1,2]. Exacerbations of patients'
pulmonary disease occur 2–3 times per year in adults and⁎ Corresponding author. University of Washington Medical Center, Campus
Box 356522, 1959 N.E. Pacific, Seattle, WA 98195, United States. Tel.: +206
543 3166; fax: +206 685 8673.
E-mail address: goss@u.washington.edu (C.H. Goss).
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.04.003present clinically with changes in cough, changes in sputum
production, increased dyspnea, decreased energy level and
appetite, weight loss, and decreases in spirometric measure-
ments [3]. These acute episodes are related to a complex
relationship between host defense and airway microbiology that
impact sputum production and airway edema and obstruction.
Respiratory viral infections may play a role in the initiation
some of these events [4]. Pulmonary exacerbations have also
been associated with the acquisition of new organisms or with a
change in the bacterial density of colonizing flora [5–8].
Standard treatment for acute exacerbations are increased airway
clearance and antibiotics. With treatment of an acute pulmonary
exacerbation, bacterial concentrations of Pseudomonas aerugi-
nosa decrease, and lung function and symptoms improve
[5,6,9]. However, there are only limited qualitative data
regarding how patients perceive these events. Two studies
have specifically addressed the changes in health related qualityd by Elsevier B.V. All rights reserved.
Table 1
Part 1 interview participants by site, age, and sex.
Recruitment site Sex Age group years n
CHRMC Female 6–10 1
Male 3
Female 11–14 2
Male 2
Female 15–18 1
Male 4
UW Female 19–25 3
Male 3
Female ≥26 3
Male 3
Total 25
246 C.H. Goss et al. / Journal of Cystic Fibrosis 8 (2009) 245–252of life pre and post an acute pulmonary exacerbation showing
improvements in multiple domains of the Chronic Respiratory
Disease Questionnaire and the Quality of Wellbeing Scores;
neither of these instruments was designed to specifically
measure respiratory symptoms in CF adults or in the adolescent
population [10,11].
A patient-derived respiratory symptom assessment specifi-
cally for patients with CF may improve our understanding and
treatment of this important clinical event. In addition, a better
understanding of key triggers that lead patients to seek medical
care may assist caregivers in earlier treatment of pulmonary
exacerbations. Such a measure might also aid early detection,
along with other indicators of exacerbations. In addition to
assessing respiratory symptoms, it is important to assess the
impacts of such symptoms, both emotional impacts and activity
impacts, in order to provide information important to patients in
the context of symptoms. In the past, non-validated symptom
scores have been used to assess the impact of intravenous
antibiotics or other interventions on CF symptoms [12–14].
While symptom assessment and dyspnea are components
assessed in many instruments [15,16], the primary focus of
these instruments has not been to quantify symptom burden and
impact. Studies in other areas of medicine (most notably pain)
have shown a discrepancy between weekly recall and daily or
momentary periods with peak symptomatology affecting
weekly recall [17–19]. In reporting symptoms with a lot of
variability (i.e. pain), recall is influenced by the most intense
symptom during the recall period. The instruments to date,
including health related quality of life instruments, have used
long recall periods (over 2 weeks); none were designed with
short recall periods; this may substantively affect the results of
such instruments.
We hypothesized that an instrument designed specifically to
assess CF symptom severity and frequency using the Day
Reconstruction Method (DRM) would provide a sensitive and
responsive outcome measure for interventions designed speci-
fically to treat symptoms. Such an instrument may be a useful
outcome measure in the evaluation of the impact of novel
therapeutic agents for CF. If successful, such an instrument
could be integrated into the definition of a CF pulmonary
exacerbation.
2. Methods
2.1. Design
This was a qualitative study in which we interviewed adults
(ages 18+ years) and adolescents (ages 12–17 years) diagnosed
with CF, and parents of children (ages 5–11 years) with CF. All
patients and parents were interviewed during an ill state defined
as a time when the participant or their parent sought medical
care beyond their usual day-to-day care; for the purpose of this
study, this was treatment as an outpatient or inpatient with oral
or intravenous antibiotics for a pulmonary exacerbation as
determined by the care provider. The definition of acute
pulmonary exacerbation did not require a specific symptom list
or change in spirometry to qualify as an exacerbation.Interviews occurred within the first 72 h of initiating treatment.
Information collected during these interviews was used to create
a CF respiratory symptom daily diary. Information was also
collected regarding the triggers that patients and their family
members used to determine whether he or she needed additional
medical care.
2.2. Sample
All participants were recruited in clinical settings. Clinic
personnel gave each prospective participant a brief introduction
to the study, and asked permission for the study recruiter to call
them with more information. By design, the participants were
divided into age categories balanced in regards to gender
(Table 1). The Children's Hospital and Regional Medical Center
(CHRMC) Institutional Review Board (IRB) approved the
study protocol for collection of data from human participants.
The University of Washington has a reciprocal agreement with
CHRMC for IRB approval.
2.3. Procedures
In conducting the qualitative interviews, the Day Recon-
struction Method (DRM) was employed [20]. The DRM is
designed to collect data describing the experiences a person has
had the day prior to the interviews, through a systematic
reconstruction method. The DRM was used in this study to
inquire specifically about the experience of respiratory
symptoms and their impacts associated with CF. This format
draws on insights from cognitive research and facilitates
retrieval from autobiographical memory. Its episodic format
attenuates biases commonly observed in retrospective reports.
The interviews were semi-structured in order to allow for
exploration of as many issues during the interview as possible
without constraining the participant to any pre-conceived
structure. Specific probes were used to illuminate setting
specific contexts of participants including home, school,
work, and community [21] and to elicit an integrated view of
CF respiratory symptomatology.
The interviews were audio-recorded and transcribed verba-
tim by a professional transcriptionist. Interviews were con-
ducted until no new symptoms or impacts were mentioned by
Fig. 1. Study population.
Table 2
Clinical characteristics of study population.
Characteristic Value Range
Children (years of age)
N 13
Female, N (% female) 4 (31%)
Non-Caucasian, N (%) 1 (8%)
Pancreatic insufficiency (%) 13 (100%)
Age (mean+/−SD) 12.1 (4.0) 4.4–17.1
Mean BMI kg/m2 (SD) 17.8 (1.6) 15.3–19.9
Mean height percentile (SD) 17.7 (26.7) 2–74
Median weight in kg (IQR) 30.8 (28.6, 45.5) 18.0–53.5
Median weight percentile (IQR) 13.5 (17.0) 2–46
Mean FEV1 in liters (SD) 1.62 (0.73) 0.84–3.34
Mean FEV1 % predicted (SD) 72.8% (22.9) 31–109
Mean FVC in liters (SD) 2.09 (0.80) 1.46–3.98
Mean FVC % predicted (SD) 81.8% (19.4) 51–114
Adults (≥19 years of age)
N 12
Female, N (% female) 6 (50%)
Non-Caucasian, N (%) 0 (0%)
Pancreatic insufficiency (%) 10 (83%)
Age (mean+/−SD) 27.8 (6.0) 20.5–37.2
Mean BMI kg/m2 (SD) 22.2 (5.4) 14.8–36.4
Mean height percentile (SD) 51.4% (37.2) 1.6–97.3
Median weight in kg (IQR) 62.0 (56.8, 65.1) 39.9–104.0
Median weight percentile (IQR) 40.9% (16.9, 64.9) 6.8–98.9
Mean FEV1 in liters (SD) 2.15 (0.58) 1.25–3.09
Mean FEV1 % predicted (SD) 58.4% (21.7) 23.7–99.1
Mean FVC in liters (SD) 3.18 (0.53) 2.20–4.04
Mean FVC % predicted (SD) 71.6% (18.0) 34.1–103.5
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ment and analysis included latent (interpretation of text) and
manifest (literal text) content analyses, and frequency tabula-
tions using software from Atlas Ti (Atlas.ti, Berlin, Germany).
For latent content analyses, passages within individual inter-
views were reviewed within the context of the entire interview
in order to determine the major theme or significant meaning.
Manifest content analyses followed latent content analyses, and
consisted of searching all transcripts for certain words or terms.
Data codes were developed for identified themes in the
interviews. At least two of the team members reviewed and
coded each interview transcript, and then the team as a whole
worked by consensus to finalize the coding and interpretation of
the data. Data collection and analysis were treated as an iterative
process; as data were collected they were preliminarily coded
and analyzed for emerging themes, and emergent themes were
further explored in successive interviews. The investigators
worked by consensus to organize codes into themes and to
identify concepts and items that are specific to acute exacer-
bation. After the text was coded and sorted, the investigators
generate a long list of items based upon the coded material and
existing instruments. Some items were taken verbatim from
interviews while others were written based upon the interview
text but keeping the items in the language of the participants as
much as possible. Items that did not assess acute exacerbation,
were poorly worded, or were redundant were eliminated. The
remaining items were reviewed, and we confirmed that all
essential categories include items.
We selected the best symptom items for inclusion and testing
using the following criteria: the item represents an area of
importance to people with cystic fibrosis, the item is in the
language of the patients, the item is likely to change with
successful treatment of the condition, the item is likely to
discriminate with severity of condition, and the item is relevant
to everyone with the condition. We also included items whichassessed the emotional and activity impacts of having CF, the
purpose of which was to contextualize the results from the
respiratory symptoms, and also to provide information relating
to more distal impacts.
The draft CF symptom and impact items were pilot tested
and submitted for cognitive interviewing. Cognitive interview-
ing is a method by which individuals assess the relevance,
importance and comprehension of the content of measures
[22,23]. Interviewees “think aloud” how they interpreted an
item and how they chose a response. This method identifies
items that have problematic language, format, or produce
confusion in the respondent. We elicited options from patients
in order to revise areas of difficulty, and this is an iterative
process. Parents, adolescents, and adults with CF participated in
the cognitive debriefing. These respondents may or may not
have participated in the qualitative item generation interviews
described above. Upon completing the instrument, each
participant was given a short debriefing interview aimed at
assessing cognitive attributes of the instrument. Standard
procedures developed at the U.S. National Center for Health
Statistics Cognitive Survey Laboratory [22,23] were used in the
debriefing process [24]. The draft instrument was also sent to
clinical experts (a list of these experts is provided in the
acknowledgements); they were asked to identify the core
symptoms and/or impact measures that in their judgment
identified an acute exacerbation. Their responses were collected
Table 3
Symptom bothersomeness ratings ranked by # of times rated.
Symptom (sorted by most to
least frequently cited)
# Times cited
(out of n=23)
Average bothersomeness rating
(1=not at all, 5=a lot)
Cough (generally) 16 3.7
Fatigue 10 3.6
Chest congestion 9 3.9
Difficulty breathing/
shortness of breath
9 3.8
Wheezing 9 2.7
Headache 6 4.0
Lack of appetite 6 2.2
Coughing up
phlegm/sputum
5 3.4
Fever 3 3.0
Tightness in chest 3 4.0
Coughing up blood 3 4.0
Runny nose 3 3.7
Sinus pain 2 4.5
Muscle ache 2 3.0
Urinary incontinence 1 5.0
Pain from cough 1 5.0
Sore throat 1 5.0
Chest pain 1 3.0
Chills 1 3.0
Sneezing 1 3.0
Vomiting 1 2.0
Nausea, stomach ache 1 5.0
Table 4
Most commonly cited triggers for seeking treatment for an acute exacerbation.
Trigger for seeking
treatment
Number of participants
citing trigger (n=25)
Percent of participants
citing trigger (%)
Constant cough 9 36
Thick, dark,
voluminous sputum
8 32
Shortness of breath 7 28
Waking in night
due to cough
5 20
Fatigue, weakness 4 16
Fullness or tightness
in chest
4 16
Chest pain 2 8
Congestion 2 8
Coughing up blood 2 8
Reducing activities
due to cough
2 8
Poor appetite 2 8
Medicine not helping
as usual
2 8
Wheezing 2 8
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identified.
3. Results
For development of the CF daily symptom diary, we
conducted a total of 25 qualitative interviews and 9 cognitive
debriefing interviews (3 adults, 4 youths, and 2 parents). Fig. 1
shows the target population, the screened population and the
enrolled population; initially 32 potential participants were
approached. Of these, 7 were unable to schedule an interview
within the time frame of the protocol. Table 1 characterizes the
qualitative interview participants in terms of age and sex. Adult
participants were recruited from the CF clinic at the University
of Washington in Seattle (UW) and child/youth participants
were recruited from the CF Clinic at Seattle's CHRMC. Table 2
summarizes all of the study population clinical data divided into
pediatric and adult. Both the pediatric and adult population had
a wide distribution of lung function [forced expiratory volume
in the first second (FEV1) of 31 to 109% and 24 to 99% of
predicted, respectively] and nutritional status [body mass index
(BMI) of 15.3 to 19.9 kg/m2 and 15 to 36 kg/m2, respectively]
encompassing mild to severe disease.
3.1. Qualitative interviews
In conducting the interviews we asked participants to tell us
which symptoms, impacts on daily life, and impacts on their
emotional state were most bothersome to them. Table 3 below
lists all the symptoms cited, and how bothersome they were
considered to be. The most frequently cited symptoms were notnecessarily rated as the most bothersome. Indeed, the most
commonly cited symptoms were felt to be between “somewhat”
and “quite a bit” bothersome; on a scale from 1 to 5
(Bothersome scale: 1=not at all, 2=a little, 3=somewhat,
4=quite a bit, and 5=a whole lot), i.e., they ranked on average
less than 4. These symptoms included cough, fatigue, chest
congestion, difficulty breathing/shortness of breath, and
wheezing. Symptoms of headache and sinus pain were
relatively common events and very bothersome. Hemoptysis
and chest tightness were both infrequent but were felt to be very
bothersome. The most commonly cited and bothersome activ-
ities included difficulty sleeping, reduction of usual activities
with increased time spent sitting or lying down, and missing
school or work. The most commonly cited emotional impact
included frustration, sadness/depression, irritability, and worry.
Twenty-one different triggers for seeking treatment for a
pulmonary exacerbation were noted during the interviews in 25
participants who were able to report a trigger. The 13 most
commonly cited triggers are noted in Table 4. Constant cough,
developing thick, dark, voluminous sputum and shortness of
breath were the most common. Nocturnal wakening due to
cough, fatigue/weakness and fullness or tightness in chest were
also commonly noted triggers. Triggers noted only once and not
noted in Table 4 were cough, fever, headache, sinus pain,
urinary incontinence from coughing, shallow breathing in a
toddler and sudden onset on symptoms. The following
statement is an example of language used to describe when an
exacerbation is occurring: “One barometer I use is in the
morning I may have a stack of Kleenexes by my bed, you know,
when I wake up. And so if I have to use them all night that —
it's like, ‘Oh, my God, look at these.’ I mean sometimes I'll
have 30 Kleenexes full of stuff that I've coughed up. And most
of the time I don't, so when I do I know it's time to call.”
We also asked the interviewees to comment regarding
whether their seeking of care was ever delayed. A number of
249C.H. Goss et al. / Journal of Cystic Fibrosis 8 (2009) 245–252clear themes emerged: difficulty in negotiating appointments
through some clinic staff, lack of access to medical insurance,
ambivalence about excessive antibiotic usage, waiting for
regularly scheduled appointments to get treatment, taking the
time out of daily life to get treatment, and denial: “Usually it just
starts off with a cold or something and at that point …you just
drop, and you should call up there and get on some medicine.
And you just let it go thinking it'll be fine, you'll get over it, and
it just adds up...”
3.2. Development of a symptom diary
In all, eight symptom items were selected for inclusion in a
new CF specific symptom diary focusing on respiratory
symptoms. These included cough, chest tightness, difficulty
breathing, wheeze, coughing up mucous, fevers and chills and
fatigue. The activity impacts included in the diary were CF
respiratory disease impacting sleep, school or work attendance,
causing reduction of usual activities, and spending more time
sitting or lying down. The emotional impacts included worry,
frustration, feeling sad or depressed and feeling cranky
(irritable). A number of symptom items noted in the interviews
were not chosen for inclusion in the symptom diary; these
symptoms are highlighted in Table 5 along with the rationale for
not including then in the symptom diary. Part of the process of
elimination of symptoms was based on the need to have a short
diary that would have limited participant burden. In total, the
new CF symptom diary contains 16 questions.
We conducted a total of 9 cognitive debriefing sessions (3
adults, 4 youth, and 2 parents). Overall, the questionnaire was
reported to be easy to complete, taking an average of 5 min. Most
of the questions were deemed easy to understand, and the
formatting was not felt to be problematic. Some changes were
made in language used in the initial draft of the instrument.
Examples of changes made to the diary as result of the cognitive
interviews include, changing the term “irritable” to “cranky” (to
make more understandable for younger respondents), reducing
“tightness or fullness in chest” to “tightness” only (fullness not
well understood or agreed upon by respondents), and changing
the response options, “a little/moderate/quite a bit/extreme” to “a
little/somewhat/a good deal/a great deal” in order to make theTable 5
Rationale for omission of symptom items in diary.
Rationale for omission Symptom
Symptoms not considered central to CF Runny nose
Sinus pain
Muscle ache
Urinary incontinence
Sneezing
Symptoms not considered respiratory in nature Headache
Lack of appetite
Sore throat
Vomiting
Nausea, stomach ache
Symptom reported too infrequently Coughing up blood
Symptoms covered under cough Chest pain
Pain from coughgradations in responses more apparent. Also the term congestion
was removed; this term was felt by the respondents to have no
clear definition. A copy of the diary is provided in Appendix A.
4. Discussion
We conducted qualitative interviews with patients and their
parents to gain insight into the pulmonary symptoms, emotional
and activity impacts and secondly triggers for seeking care in
patients with CF. Six pulmonary symptoms were identified as
central to CF: cough, sputum production, wheeze, chest
tightness, difficulty breathing/shortness of breath, and fever.
Emotional impacts included frustration, sadness/depression,
irritability, worry, difficulty sleeping; while activity impacts
included time spent sitting or lying down, reduction of usual
activities, and missing school or work. These data were then
compiled into a CF specific symptom and impact diary called
the CF Respiratory Symptom Diary (CFRSD). In all, eight
symptom items were selected for inclusion on the new diary.
Our study is not the first to assess respiratory symptoms in
CF. However, prior qualitative studies in CF have focused
mainly on the treatment burden [25], gender differences [24],
transition [26,27], encounters in primary care [28] and lung
transplantation and end of life care [29–31]. None have focused
on the most common clinical event to all CF patients that of
worsening respiratory symptoms associated with an acute
pulmonary exacerbation of their disease. This is the first
qualitative study to assess patient reported respiratory symp-
toms associated with respiratory illnesses in CF, and this is the
first patient reported diary developed specifically to assess
respiratory symptoms in CF. Much of the information gleaned
from this study supports physician-derived symptom measures
established for assessment of pulmonary exacerbation
[9,12,14,32] and respiratory symptoms assessed in current
health related quality of life instruments [15,33–40]. Not only is
this qualitative assessment novel, we were able to assess
triggers that patient's employ to seek care. No prior studies have
assessed triggers for seeking care. The structured interviews and
measures that we have performed can elicit the patient's
perspective concisely and consistently in a more standardized
fashion than can clinicians; this can yield a more uniform
perspective on patients' symptoms and the triggers they employ
to seek care. Thus our data, using qualitative methods, has
affirmed our prior understanding of the symptom profile of CF
patients who are being treated for an acute pulmonary
exacerbation, and provides additional information regarding
the triggers that those patients use when deciding to seek care.
With the information from qualitative interviews in this
study, we were able to create the CF Respiratory Symptom
Diary (CFRSD). In the past, several investigators have used
non-validated symptom scores developed by physicians to
assess the impact of intravenous antibiotics or other interven-
tions on CF symptoms. Smith et al. created an acute change
score; this score was devised to standardize the physician
assessment of patients during hospitalizations for CF pulmon-
ary exacerbation [6]. The score included physician assessment
of activity level, cough, appetite, chest exam, weight and
250 C.H. Goss et al. / Journal of Cystic Fibrosis 8 (2009) 245–252respiratory effort and were not patient derived. A second
symptom score was developed and used in a clinical trial
involving a vaccine against respiratory synytial virus, the Acute
Respiratory Illness Checklist (ARIC) [41]. It was used as a
symptom score to identify patients with lower respiratory tract
infections, thus capturing a wider spectrum of CF exacerbations
in study participants; it was not designed as an acute change
instrument and was not patient-derived. Disease-specific quality
of life instruments often have symptom domains that can be
used to derive a symptom sub-score [15,16,34–38,42,43]. The
symptom scales, however, are not developed to assess acute
change in respiratory symptoms, rather changes in symptoms
over the variable periods of recall. The respiratory symptom
scale of one instrument (CFQ-R) is currently being used to
assess response to inhaled antibiotics and other products in
development [35,44,45]. We believe that this instrument may
add substantively to the already available CFQ-R, the most
widely used questionnaire assessing CF health related quality of
life [16,34,35]. The current instrument can be used daily, has
only a 24 hour recall period (unlike the CFQ-R which has a two
week recall), and focuses on more respiratory symptoms
specifying both the frequency and severity of such symptoms.
The instrument eliminates issues related to recall of symptoms
and expands the number and description of respiratory
symptoms currently obtained in existing instruments.
A number of other instruments that specifically assess the
symptom of dyspnea have been studied in the CF population.
These include the Borg scale, the Modified Medical Research
Council Scale (MRC) [46,47], the use of a Visual Analog Scale
(VAS) to assess dyspnea [48,49], 15 count Breathlessness score
[50], the Phonation test [49], and the University of California at
San Diego (UCSD) Shortness of Breath Questionnaire [51].
These scores have been developed to assess dyspnea after
exercise and dyspnea related to activities of daily living.
Because they are limited to only one symptom, dyspnea, they
are unlikely to capture the full spectrum of CF respiratory
symptoms captured by the CFRSD.
Symptom scales for pulmonary disease other than CF have
not been used in CF. These scales could conceivably be applied
to CF patients; however, these patient populations differ quite
substantially in age, symptom profile, and natural history. They
include the Breathlessness, Cough, and Sputum Scale (BCSS),
the Clinical COPD Questionnaire (CCQ) and the Chronic
Bronchitis Symptoms Assessment Scale (CBSAS) for chronic
obstructive pulmonary disease [52–55]. It is not known how
these instruments developed for either asthma or COPD will
perform in the CF population. Although CF patients have some
of the same symptoms as patients with COPD; their perception
of these symptoms may differ greatly. In order to show
responsivity to changes in symptoms, an instrument must
accurately reflect those symptoms. Instruments established in
one disease (COPD) may not translate very well to CF. Thus,
these instruments are unlikely to supplant an instrument like the
CFRSD.
There are several important limitations to this study. First,
our patient population was from two programs in the U.S.
Pacific Northwest. National and regional differences may existregarding how patients describe their experiences. However, the
symptoms elicited were similar to those developed previously
by clinicians from diverse geographic regions making it
unlikely that these symptoms are unique to the U.S. Pacific
Northwest [12–14,32]. Another important limitation of this
work is the relatively small number of children ages 5–11 and
their families involved in this research. A larger sample of
family members of children ages 5–11 years may elucidate
more concepts and language not found in the current study.
Further validation of this instrument is required in small
children, adolescents and adults. We are currently in the process
of applying this questionnaire in a number of clinical trials to
assess its validity and responsiveness [56].
5. Conclusions
CF respiratory symptoms reported by patients in this
qualitative study are similar to the diverse array of symptoms
established in physician derived instruments. Triggers for
seeking care were diverse but centered on cough frequency,
sputum volume and shortness of breath. The diverse number of
triggers for seeking care will complicate attempts to standardize
approaches to care for CF patients with acute pulmonary
exacerbation. We have been able to compile the most
burdensome and frequent symptoms into a new questionnaire,
the CFRSD. A CF-specific symptom questionnaire is clearly
needed to ensure that one is accurately capturing symptoms.
This diary may add to CF clinical research and CF clinical care.
Such an instrument could be used to screen for symptoms when
patients come to clinic; it could also be employed for home
based monitoring of respiratory symptoms. The strengths of this
study include that it was conducted with patients and parents
rather than clinicians, and it is the first study to develop such
outcome measures through patient and parent input.
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